ASMB Stock Overview
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Assembly Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.92 |
52 Week High | US$20.04 |
52 Week Low | US$7.69 |
Beta | 0.65 |
11 Month Change | -1.39% |
3 Month Change | -1.58% |
1 Year Change | 39.70% |
33 Year Change | -66.12% |
5 Year Change | -89.42% |
Change since IPO | -96.05% |
Recent News & Updates
Recent updates
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end
Oct 05Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce
Jul 20We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Sep 03Assembly Biosciences announces resignation of CFO
Jun 02Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook
Mar 24Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares
Feb 05We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Dec 14Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Nov 16Assembly Biosciences EPS beats by $0.69, beats on revenue
Nov 05Shareholder Returns
ASMB | US Biotechs | US Market | |
---|---|---|---|
7D | 14.2% | 5.3% | 4.9% |
1Y | 39.7% | 15.7% | 25.6% |
Return vs Industry: ASMB exceeded the US Biotechs industry which returned 13.4% over the past year.
Return vs Market: ASMB exceeded the US Market which returned 24.7% over the past year.
Price Volatility
ASMB volatility | |
---|---|
ASMB Average Weekly Movement | 8.4% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ASMB has not had significant price volatility in the past 3 months.
Volatility Over Time: ASMB's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
Assembly Biosciences, Inc. Fundamentals Summary
ASMB fundamental statistics | |
---|---|
Market cap | US$90.74m |
Earnings (TTM) | -US$45.61m |
Revenue (TTM) | US$21.48m |
4.4x
P/S Ratio-2.1x
P/E RatioIs ASMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ASMB income statement (TTM) | |
---|---|
Revenue | US$21.48m |
Cost of Revenue | US$49.97m |
Gross Profit | -US$28.49m |
Other Expenses | US$17.12m |
Earnings | -US$45.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -7.19 |
Gross Margin | -132.61% |
Net Profit Margin | -212.33% |
Debt/Equity Ratio | 0% |
How did ASMB perform over the long term?
See historical performance and comparison